BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 184 filers reported holding BRIDGEBIO PHARMA INC in Q3 2022. The put-call ratio across all filers is 0.89 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $390,000 | +12.4% | 39,243 | +2.6% | 0.07% | +32.1% |
| Q2 2022 | $347,000 | -10.6% | 38,243 | 0.0% | 0.05% | +8.2% |
| Q1 2022 | $388,000 | -32.0% | 38,243 | +11.7% | 0.05% | -30.0% |
| Q4 2021 | $571,000 | -58.5% | 34,243 | +16.7% | 0.07% | -51.7% |
| Q3 2021 | $1,375,000 | -23.1% | 29,345 | 0.0% | 0.14% | -27.9% |
| Q2 2021 | $1,789,000 | +1.0% | 29,345 | +2.1% | 0.20% | -15.9% |
| Q1 2021 | $1,771,000 | -13.4% | 28,743 | 0.0% | 0.24% | -24.1% |
| Q4 2020 | $2,044,000 | +92.8% | 28,743 | +1.8% | 0.32% | +53.7% |
| Q3 2020 | $1,060,000 | +15.1% | 28,243 | 0.0% | 0.20% | +9.0% |
| Q2 2020 | $921,000 | +12.5% | 28,243 | 0.0% | 0.19% | -4.1% |
| Q1 2020 | $819,000 | +290.0% | 28,243 | +370.7% | 0.20% | +390.0% |
| Q4 2019 | $210,000 | – | 6,000 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 6,068,125 | $160,016,456 | 65.94% |
| Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $819,077,805 | 28.79% |
| Cormorant Asset Management, LP | 4,662,530 | $122,950,916 | 7.17% |
| Frazier Life Sciences Management, L.P. | 2,725,949 | $71,883,275 | 4.77% |
| Octagon Capital Advisors LP | 971,639 | $25,622,120 | 3.94% |
| M28 Capital Management LP | 121,200 | $3,196,044 | 3.66% |
| VIKING GLOBAL INVESTORS LP | 25,120,991 | $662,440,533 | 2.69% |
| BOONE CAPITAL MANAGEMENT LLC | 313,381 | $8,263,857 | 2.61% |
| Fernwood Investment Management, LLC | 235,620 | $6,213,299 | 2.23% |
| SOUTHPORT MANAGEMENT, L.L.C. | 15,000 | $395,550 | 2.15% |